Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)

被引：0

作者：

Zhan, L. J. ^{[1
]}

Barghout, S. ^{[1
]}

Raptis, S. ^{[1
]}

Al-Agha, F. ^{[1
]}

Popovacki, A. ^{[2
]}

Esfahanian, N. ^{[1
]}

Kasymjanova, G. ^{[3
]}

Proulx-Rocray, F. ^{[4
]}

Chan, S. ^{[5
]}

Richardson, M. ^{[6
]}

Brown, M. C.

Patel, D.

Dean, M. L. ^{[7
]}

Navani, V. ^{[7
]}

Moore, E.

Carvery, L. ^{[2
]}

Yan, E.

Cleary-Gosine, J. ^{[2
]}

Gibson, A. J. ^{[7
]}

Hubley, L. ^{[2
]}

Balaratnam, K. ^{[1
]}

Ngo, T. ^{[2
]}

Gill, A. ^{[9
]}

Black, M. ^{[10
]}

Sacher, A. ^{[1
]}

Bradbury, P. A. ^{[1
]}

Shepherd, F. ^{[1
]}

Leighl, N. ^{[1
]}

Cheema, P. ^{[9
]}

Kuruvilla, S. ^{[10
]}

Agulnik, J. ^{[3
]}

Banerji, S. ^{[8
]}

Juergens, R. ^{[5
]}

Blais, N.

Cheung, W. ^{[7
]}

Wheatley-Price, P. ^{[6
]}

Liu, G. ^{[1
]}

Snow, S. ^{[2
]}

机构：

[1] UHN, Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] QEII Hlth Sci Ctr, Halifax, NS, Canada

[3] Jewish Gen Hosp, Montreal, PQ, Canada

[4] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[5] Hamilton Hlth Sci, Juravinski Canc Ctr, Hamilton, ON, Canada

[6] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[7] Tom Baker Canc Clin, Calgary, AB, Canada

[8] CancerCare Manitoba Res Inst, Winnipeg, MB, Canada

[9] William Osler Hlth Syst, Brampton Civic Hosp, Brampton, ON, Canada

[10] London Hlth Sci Ctr, London, ON, Canada

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

KRAS G12C; Advanced NSCLC; Real-World Data;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP12.03-02

引用

页码：S680 / S680

页数：1

共 50 条

[21] A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system
Wu, Lisha
Xu, Maosheng
Li, Xueqin
Aierken, Dilinuer
Yu, Jinxiu
Qin, Tao
FRONTIERS IN PHARMACOLOGY, 2024, 15
[22] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
Reck, M.
Spira, A.
Besse, B.
Wolf, J.
Skoulidis, F.
Borghaei, H.
Goto, K.
Park, K.
Griesinger, F.
Felip, E.
Boyer, M.
Barrios, C. H.
Goss, G.
Yang, H.
Obiozor, C.
Ramalingam, S. S.
ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
[23] Liquid biopsy to track KRAS G12C mutation at progressive disease in patients with advanced non-small cell lung cancer (NSCLC)
De Renzi, G.
Nicolazzo, C.
Pisegna, S.
Belardinilli, F.
Bottillo, I.
Grammatico, P.
Giannini, G.
Gelibter, A. J.
Gazzaniga, P.
ANNALS OF ONCOLOGY, 2021, 32 : S983 - S983
[24] Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program
Passiglia, Francesco
Reale, Maria Lucia
Lo Russo, Giuseppe
Pasello, Giulia
Minuti, Gabriele
Bulotta, Alessandra
Galetta, Domenico
Pelizzari, Giacomo
Sini, Claudio
Bria, Emilio
Roca, Elisa
Pilotto, Sara
Genova, Carlo
Metro, Giulio
Citarella, Fabrizio
Chiari, Rita
Cortinovis, Diego
Delmonte, Angelo
Russo, Alessandro
Tiseo, Marcello
Cerea, Giulio
Carta, Annamaria
Scotti, Vieri
Vavala, Tiziana
Brambilla, Marta
Buffoni, Lucio
Buosi, Roberta
Catania, Chiara
Gori, Stefania
Grisanti, Salvatore
Agustoni, Francesco
Garbo, Edoardo
Malapelle, Umberto
Novello, Silvia
LUNG CANCER, 2024, 187
[25] Interrater Agreement of the Nancy Histologic Index in Previously Treated Ulcerative Colitis Biopsies: A Real-World Multi-Institutional Experience Across the United States
Shenoy, Krithika
Li, Jiannan
Allende, Daniela
Ballentine, Samuel
Byrnes, Kathleen
Deepak, Parakkal
Dessain, Alicia
Esnakula, Ashwini
Gonzalez, Raul
Gui, Xianyong
Lee, Hwajeong
Lin, Jingmei
Mattay, Shivani
Setia, Namrata
Wang, Hanlin
Yang, Zhaohai
Zhang, Xuchen
Liu, Xiuli
LABORATORY INVESTIGATION, 2024, 104 (03) : S814 - S815
[26] Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
Hong, D. S.
Bang, Y. -J.
Barlesi, F.
Durm, G.
Falchook, G.
Govindan, R.
Dy, G.
Park, K.
Strickler, J.
Burns, T.
Kim, J.
Ang, A.
Lipford, J. R.
Ngarmchamnanrith, G.
Anderson, A.
Li, B. T.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S29
[27] Prescription Patterns After the Approval of Dupilumab, Abrocitinib, Baricitinib, and Upadacitinib in Adults with Atopic Dermatitis: A Real-World Evidence from a Multi-Institutional Database in Taiwan
Lee, Wei-Ting
Chang, Kai-Cheng
Chen, Hui-Yu
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 156 - 156
[28] Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
Aggarwal, Charu
Parkar, Lamisa
Huerga, Iker
Sasser, Kate
Nimeiri, Halla
Korytowsky, Beata
Patel, Jyoti D.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB)
Aggarwal, S.
Whipple, S.
Hsu, H.
Tu, H.
Carrigan, G.
Wang, X.
Ngarmchamnanrith, G.
Chia, V.
ANNALS OF ONCOLOGY, 2020, 31 : S860 - S860
[30] Real-world prescription pattern among patients with inflammatory bowel disease in Taiwan: A multi-institutional electronic medical records database analysis
Kou, Chon Hou
Chang, Kaicheng
Chen, Hui-Yu
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 354 - 355

← 1 2 3 4 5 →